| Literature DB >> 31057296 |
Kenya Kamimura1, Akira Sakamaki2, Hiroteru Kamimura2, Toru Setsu2, Takeshi Yokoo2, Masaaki Takamura2, Shuji Terai2.
Abstract
The aging of the organ function causes sensitivity to the disease progression and need careful consideration for the medical treatment. With the increase of aging population, the opportunity to provide medical treatment for people in very old age is rapidly increasing therefore, the understanding of the various physiological changes of cellular function, size and function of organs are essential for the decision of therapeutic options. Among the various chronic conditions seen in elderly people, we have focused on liver cirrhosis, since despite specific therapeutic options for many of liver diseases including direct acting antivirals for hepatitis C virus, nucleoside analogs for hepatitis B, and corticosteroids for autoimmune hepatitis, there is currently no standard therapy to treat liver cirrhosis, which is the final stage of these liver diseases. Therefore, management of the various symptoms of liver cirrhosis is essential, and aging-related parameters must be considered in the decision making for therapeutic strategies and dosage of the available medicine. In this mini-review, we have summarized the therapeutic options to manage various symptoms of liver cirrhosis, carefully considering the physiological changes of various organs associated with aging.Entities:
Keywords: Aging; Elderly patients; Liver cirrhosis; Quality of life
Mesh:
Year: 2019 PMID: 31057296 PMCID: PMC6478616 DOI: 10.3748/wjg.v25.i15.1817
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Morphological and functional aging of the liver
| Reduced liver weight | ||
| Reduced blood flow to the liver | ||
| Loss of metabolic function | ||
| Loss of detoxification | ||
| Decreased growth factor expression | ||
Conditions to consider when determining therapeutic options
| Decreased cardiac function | Use of endoscopic therapy |
| Use of beta-blockers | |
| Increase in blood pressure caused by molecular targeted agent | |
| Decreased renal function | Use of contrast medium |
| Use of interventional radiology for hepatocellular carcinoma | |
| Rapid change in circulation dynamics | |
| Decreased respiratory function | Aspiration pneumonia |
| Ease of electrolyte abnormalities | Higher risk of using diuretics |
| Dementia | Difficulty in differentiating hepatic encephalopathy from dementia and cerebrovascular diseases |
| Aging of gut microbiota | Hepatic encephalopathy |
| Loss of bone density | Osteoporosis |
| Risk of fall-related injury | |
| Loss of muscle volume | Sarcopenia |
| Risk of fall-related injury | |
| Dry skin | Pruritus |
| Hand–foot syndrome caused by molecular targeted agent |
The complications and management of liver cirrhosis in elderly patients need careful considerations
| Ascites | Sodium restrictions | Electrolyte abnormalities |
| Anti-mineral corticoid | Changes in circulation dynamics | |
| Furosemide | Body weight | |
| Torasemide | Pulse and blood pressure | |
| Albumin infusion | Verification of blood biochemistry and urinalysis | |
| Hepatic encephalopathy | Optimization of bowel movement | Diarrhea |
| Laxatives | Frequent diarrhea that causes electrolyte abnormalities | |
| Branched-chain amino acids | Skin troubles from frequent defecation | |
| Synthetic disaccharide lactulose | Dehydration | |
| Rifaximin | Cardiac stress and fluctuation of electrolytes | |
| Intravenous drip infusion of Fischer solution | ||
| Gastrointestinal bleeding/varices | Non-selective beta-blockers | Arrhythmia |
| Fluctuation of blood pressure | ||
| Cardiac failure | ||
| Endoscopic therapy | Aspiration pneumonia | |
| Sarcopenia | Risk of fall-related injury | Nutritional monitoring (serum markers including the albumin, cholesterol level) |
| Muscle volume | ||
| Administration of branched-chain amino acid preparations | ||
| Skin symptoms | Skin moisturisers | Likely to have dry skin |
| Bile salts | Frequently suffer from wound infections and persistent skin inflammation | |
| Rifampicin | Nalfurafine hydrochloride | |
| Anti-histamines | ||
| Hepatocellular carcinoma | Use of phase contrast for the diagnosis | Renal function |
| Surgical therapy | Cardiac function | |
| Transarterial chemotherapy | Bone marrow function | |
| Needle guided local therapy | ||
| Molecular targeted therapies | History of cerebral bleeding, | |
| Hypertension | ||
| Renal function | ||
| Cirrhotic cardiomyopathy | Cardiac function | |
| Spontaneous bacterial peritonitis | Sarcopenia | |
| Hepato-renal syndrome | ||
| Acute and chronic kidney injury | ||
| Hyponatremia | Further clinical trials and information from retrospective studies are necessary | |
Figure 1Summary of the changes of the body and possible risks treating the complication of the liver cirrhosis.